BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Epigenomic pathways in cancer and in cancer immunotherapy - Shelle
 y Berger\, Epigenetics Institute\, Departments of Cell and Developmental B
 iology\, Genetics\, Biology\, University of Pennsylvania
DTSTART:20170223T160000Z
DTEND:20170223T170000Z
UID:TALK62356@talks.cam.ac.uk
CONTACT:Kate Davenport
DESCRIPTION:Cancer is both a genomic and epigenomic disease\, given that n
 umerous chromatin pathways have been implicated as drivers in cancer.  Our
  study of p53 in human cancer has revealed an important role of epigenomic
  regulation in several cancers involving gain-of-function mutant p53\, and
  in teratocarcinoma cancer\, which involves wild type p53.  In the former 
 case\, mutant p53 drives expression of gene-activating histone modifiers\,
  and in the latter case\, wild type p53 is modified by gene-repressive mod
 ifications – in both cases permitting the expression of growth accelerat
 ing genes and pathways.\nImmunotherapy is a new and exciting area of clini
 cal cancer treatment.  While some individuals respond\, others show resist
 ance.  We are investigating epigenetic pathways that may inhibit effective
  cancer immunotherapy\, and other epigenetic pathways that may provide exc
 eptionally potent response.  \n
LOCATION:CRUK CI Lecture Theatre
END:VEVENT
END:VCALENDAR